The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
The Chemours CompanyNYSE: CC
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$413M, compared with -$103M a year earlier. Trailing-twelve-month EBITDA was -$166M. Over 3 fiscal years it compounded at -34.7% a year.
Context
- EBITDA amounted to 5.7% of revenue in FY2025, down 6.3 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of $728.74M (+119.5%) for the fiscal year ending Dec 2026, a step up from the -52.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$413M-430.4% QoQ
- Last fiscal yearDec 2025
- $332M-52.0% YoY
- LTMJun 2026
- -$166M-151.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -301.0% | -0.4% | +300.6 pp |
| 1 year | -52.0% | +119.5% | +171.5 pp |
| 3-year CAGR | -34.7% | +43.2% | +77.9 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 332M USD
- Year-over-year change
- -52.0%
- 4-year CAGR
- -27.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 332M | -52.0% |
| FY2024 | 2024-12-31 | 692M | +251.3% |
| FY2023 | 2023-12-31 | 197M | -83.5% |
| FY2022 | 2022-12-31 | 1.2B | +1.4% |
| FY2021 | 2021-12-31 | 1.18B | — |
EBITDA vs competitors
How CC compares with its peers on the latest reported figures
- CC's LTM Jun 2026 EBITDA of -$166M is the 18th highest of the 19 companies compared; the peer median is $503.4M.
- Its year-over-year change of -151.6% is the 17th highest of 19, against a peer median of +12.1%.
- EBITDA amounts to 2.9% of revenue for CC, versus a peer median of 17.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $13.43B | +6.1% | +6.9% | 37.9% | |
| LTM Sep 2026 | $3.73B | +697.9% | -42.8% | 11.7% | |
| LTM Jun 2026 | $2.78B | +13.2% | +11.6% | 16.9% | |
| LTM Jun 2026 | $1.49B | +94.5% | — | 14.9% | |
| LTM Jun 2026 | $986M | -5.2% | +13.9% | 19.1% | |
| LTM Sep 2026 | $772.4M | -42.3% | -44.1% | 5.9% | |
| LTM Jun 2026 | $690M | -14.9% | +13.9% | 19.0% | |
| LTM Sep 2026 | $684M | +41.6% | — | 6.0% | |
| LTM Aug 2026 | $540.79M | +11.0% | +2.4% | 15.2% | |
| LTM Sep 2026 | $466M | -1.9% | -13.5% | 13.4% | |
| LTM Jun 2026 | $380M | +176.5% | — | 20.6% | |
| LTM Jun 2026 | $301.51M | +13.9% | +2.5% | 17.7% | |
| LTM Sep 2026 | $270.06M | +24.6% | +8.6% | 17.8% | |
| LTM Sep 2026 | $232.84M | +46.9% | +6.3% | 11.5% | |
| LTM Mar 2026 | $151.69M | +37.7% | -13.1% | 18.5% | |
| LTM Mar 2026 | $139.3M | -31.9% | -19.6% | 7.8% | |
| LTM Mar 2026 | -$42.1M | -2075.7% | — | 38.2% | |
| LTM Jun 2026 | -$166M | -151.6% | -34.7% | 2.9% | |
| LTM Jun 2026 | -$300.15M | -303.2% | — | 39.6% | |
| Peer median (excluding CC) | $503.4M | +12.1% | +2.5% | 17.3% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.35B | 6.83B | 6.08B | 5.78B | 5.81B |
| Cost of Revenue | 4.96B | 5.22B | 4.77B | 4.63B | 4.91B |
| Gross Profit | 1.38B | 1.62B | 1.31B | 1.15B | 902M |
| Gross Margin | 21.8% | 23.7% | 21.5% | 19.9% | 15.5% |
| Research & Development | 107M | 118M | 108M | 109M | 108M |
| Selling, General & Admin | 592M | 710M | 1.29B | 585M | 799M |
| Operating Expenses | 707M | 830M | 1.43B | 708M | 907M |
| Depreciation & Amortization | 317M | 291M | 307M | 301M | 340M |
| EBITDA | 1.18B | 1.2B | 197M | 692M | 332M |
| EBITDA Margin | 18.6% | 17.5% | 3.2% | 12.0% | 5.7% |
| Operating Income | 674M | 786M | (123M) | 443M | (5M) |
| Operating Margin | 10.6% | 11.5% | -2.0% | 7.7% | -0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 185M | 163M | 208M | 264M | 269M |
| Other Income / Expenses | 2M | (45M) | (195M) | (316M) | (272M) |
| Income Before Tax | 676M | 741M | (318M) | 127M | (277M) |
| Pre-Tax Margin | 10.7% | 10.8% | -5.2% | 2.2% | -4.8% |
| Income Tax Expense | 68M | 163M | (81M) | 41M | 109M |
| Net Income | 608M | 578M | (238M) | 86M | (386M) |
| Net Margin | 9.6% | 8.5% | -3.9% | 1.5% | -6.6% |
| EPS (Basic) | 3.69 | 3.72 | (1.60) | 0.58 | (2.57) |
| EPS (Diluted) | 3.60 | 3.65 | (1.60) | 0.57 | (2.56) |
| Weighted Avg Shares | 164.94M | 155.36M | 148.91M | 149.49M | 150.35M |
| Weighted Avg Shares (Diluted) | 168.7M | 158.3M | 148.91M | 150.01M | 150.55M |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.